Elevation Oncology, Inc. is an oncology company. Co. is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. We show 15 historical shares outstanding datapoints in our ELEV shares outstanding history coverage, used to compute ELEV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ELEV market cap history over the course of time is important for investors
interested in comparing ELEV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ELEV versus a peer is one thing; comparing
ELEV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ELEV can fluctuate over the course of history.
With this page we aim to empower investors researching ELEV by allowing them to research the ELEV market cap history. |
Free ELEV Email Alerts:
Video: The Importance of Market Cap
